Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 7/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119395 | 0.86 | BCAT2 (0.76) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL27273135 | 0.86 | BCAT2 (0.76) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL265344 | 0.84 | HPGD (1.00) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL23209156 | 0.84 | BCAT2 (0.72) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL23267317 | 0.82 | BCAT2 (0.70) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL263943 | 0.81 | KDM4E (1.00) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL23233811 | 0.81 | BCAT2 (0.68) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL264414 | 0.79 | BCAT2 (0.65) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL25908842 | 0.78 | PDPK1 (1.00) | BCAT2HPGDKDM4ELMNAGAA | |
| SCHEMBL23237561 | 0.76 | THRB (0.65) | BCAT2HPGDKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| CN-114929712-B | Thienopyrimidinones as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-114945408-B | Thienopyrimidinones as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11578080-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| US-11578080-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-14 | — | — | US | disclosed |
| CN-114945408-A | Thienopyrimidinones as TRPA1 inhibitors | 勃林格殷格翰国际有限公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-4045509-A1 | THIENOPYRIMIDONES AS TRPA1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045144-A1 | THIENOPYRIMIDONES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-20210395267-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20210395267-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INT (DE) | 2021-12-23 | — | — | US | disclosed |
| US-20110212103-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | BCAT2 2562/4885HPGD 1832/4885KDM4E 4160/4885 |
| US-11578080-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | BCAT2 4098/4885HPGD 1506/4885KDM4E 3740/4885 |
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | BCAT2 1011/4885HPGD 226/4885KDM4E 3676/4885 |
| US-20210395267-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | BCAT2 4266/4885HPGD 2065/4885KDM4E 3563/4885 |
| US-20110212103-A1 | THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS | CMPK1, DTYMK, NEK2 | BCAT2 2273/4885HPGD 1607/4885KDM4E 2497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.